Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Operating Expenses (2016 - 2025)

Marimed has reported Operating Expenses over the past 15 years, most recently at $15.0 million for Q4 2025.

  • Quarterly Operating Expenses rose 6.39% to $15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.7 million through Dec 2025, up 1.18% year-over-year, with the annual reading at $60.7 million for FY2025, 1.16% up from the prior year.
  • Operating Expenses was $15.0 million for Q4 2025 at Marimed, up from $14.8 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $16.0 million in Q1 2025 and troughed at $6.1 million in Q1 2021.
  • The 5-year median for Operating Expenses is $13.8 million (2023), against an average of $12.8 million.
  • Year-over-year, Operating Expenses surged 299.08% in 2021 and then dropped 10.95% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $14.3 million in 2021, then decreased by 10.95% to $12.7 million in 2022, then grew by 17.16% to $14.9 million in 2023, then fell by 5.25% to $14.1 million in 2024, then grew by 6.39% to $15.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Operating Expenses are $15.0 million (Q4 2025), $14.8 million (Q3 2025), and $14.9 million (Q2 2025).